Market closedNon-fractional
Haemonetics/HAE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Ticker
HAE
Sector
Healthcare
Trading on
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Boston, United States
Employees
3,657
Website
www.haemonetics.com
Haemonetics Metrics
BasicAdvanced
$4.6B
Market cap
39.56
P/E ratio
$2.29
EPS
0.33
Beta
-
Dividend rate
Price and volume
Market cap
$4.6B
Beta
0.33
Financial strength
Current ratio
2.56
Quick ratio
1.288
Long term debt to equity
83.083
Total debt to equity
84.149
Interest coverage (TTM)
10.61%
Management effectiveness
Return on assets (TTM)
5.87%
Return on equity (TTM)
13.22%
Valuation
Price to earnings (TTM)
39.563
Price to revenue (TTM)
3.509
Price to book
4.79
Price to tangible book (TTM)
-409
Price to free cash flow (TTM)
39.79
Growth
Revenue change (TTM)
12.01%
Earnings per share change (TTM)
2.23%
3-year revenue growth (CAGR)
14.57%
3-year earnings per share growth (CAGR)
13.89%
What the Analysts think about Haemonetics
Analyst Ratings
Majority rating from 7 analysts.
Haemonetics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$343M
2.08%
Net income
$20M
-34.94%
Profit margin
5.91%
-36.31%
Haemonetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
$1.05
$0.99
$1.04
$0.90
-
Expected
$0.73
$0.89
$0.94
$0.89
$1.01
Surprise
43.74%
11.47%
10.47%
0.98%
-
Haemonetics News
AllArticlesVideos
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
PRNewsWire·3 weeks ago
Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
PRNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haemonetics stock?
Haemonetics (HAE) has a market cap of $4.6B as of July 26, 2024.
What is the P/E ratio for Haemonetics stock?
The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 39.56 as of July 26, 2024.
Does Haemonetics stock pay dividends?
No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Haemonetics dividend payment date?
Haemonetics (HAE) stock does not pay dividends to its shareholders.
What is the beta indicator for Haemonetics?
Haemonetics (HAE) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Haemonetics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.